Nasus Pharma Ltd. NSRX

Nasus Pharma Ltd. (NSRX) received FDA clearance to initiate a clinical study of NS002 for anaphylaxis treatment. FDA clearance to start NS002 clinical study represents a key regulatory milestone advancing pipeline development.

Nasus Pharma Ltd. released financial results for the first half of 2026. Half-year results provide performance data that can shift investor views and valuation.

Nasus Pharma Ltd. (NSRX) released first half 2026 financial results. Half-year financial results deliver performance data that can shift near-term sentiment but rarely transform company trajectory alone.

Nasus Pharma Ltd. (NSRX) released first half 2026 financial results and a business update. Half-year financial results and business updates can shift short-term market sentiment and valuation.

Nasus Pharma Ltd. appoints pharmaceutical industry veteran Brendan P. O'Grady as Chief Executive Officer to lead strategic growth. New CEO appointment represents a major strategic move that can significantly shift company trajectory and investor sentiment.

Nasus Pharma Ltd. (NSRX) schedules a KOL event for NS002 in June. NS002 KOL event may moderately influence market perception of pipeline progress.

Nasus Pharma reports positive preclinical pharmacokinetic and safety data for intranasal ondansetron formulation NS003. Positive preclinical results for NS003 can support further pipeline progress and modestly lift market sentiment for Nasus Pharma.

Nasus Pharma Ltd. (NSRX) receives initiating coverage highlighting its potential in nasal drug delivery solutions. Initiating coverage raises visibility and may moderately lift investor interest in NSRX's nasal technology.

Nasus Pharma Ltd. (NSRX) advances NS002 toward pivotal study after positive Phase 2 results, reports annual results, and provides business update. Advancing to pivotal study post-positive Phase 2 marks major clinical progress poised to drive significant valuation uplift and investor sentiment.

BriefCast published the transcript of Nasus Pharma Ltd. (NSRX) webinar detailing positive topline results from the NS002 Phase 2 trial. Positive Phase 2 topline results for NS002 mark a transformative clinical milestone poised to redefine NSRX's pipeline, partnerships, and market valuation.

Nasus Pharma Ltd. (NSRX) announced topline results from the Phase II clinical trial of NS002, demonstrating statistically significant improvement in primary endpoint versus placebo with a favorable safety profile. Phase II topline success for lead candidate NS002 positions NSRX for potential Phase III advancement and partnership deals, fundamentally redefining its biotech prospects.

Nasus Pharma Ltd. (NSRX) announced positive top-line data from Phase 2 clinical study of NS002, achieving significantly superior and faster epinephrine delivery compared to EpiPen with accelerated speed to therapeutic threshold. Positive Phase 2 results outperforming EpiPen signal major clinical milestone that could drive partnerships, funding, and stock gains for NSRX.

Nasus Pharma Ltd. (NSRX) will present topline analysis from Phase 2 single and repeat dose clinical study of NS002 intranasal epinephrine powder. Phase 2 topline data presentation for intranasal epinephrine advances NSRX's pipeline toward potential approval and commercialization.

Nasus Pharma Ltd. (NSRX) will present data at AAAAI 2026 demonstrating superior nasal deposition and stability of its intranasal epinephrine powder. Data presentation at a major conference highlights product advantages in nasal delivery, potentially influencing investor sentiment and competitive positioning without guaranteeing commercialization.

Nasus Pharma Ltd. has successfully closed a private placement, raising $15.0 million. The funds will be utilized to advance the company's clinical programs and support ongoing operations. This financing is expected to enhance the company's financial position and facilitate the development of its product pipeline. The private placement significantly boosts financial resources, enabling strategic advancements in clinical programs.

Nasus Pharma Ltd. (NSRX) has announced the pricing of a private placement amounting to $15.0 million. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The private placement is anticipated to close on or about October 30, 2023, subject to customary closing conditions. The private placement will provide additional capital, which may moderately influence the company's financial performance and development efforts.

Nasus Pharma Ltd. announced positive interim results from its Phase 2 clinical study of NS002, an intranasal epinephrine powder designed for the treatment of anaphylaxis. The study demonstrated favorable safety and efficacy profiles, with participants showing significant improvements in key metrics. These results support the potential of NS002 as a viable alternative to traditional epinephrine delivery methods, which could enhance patient compliance and outcomes. The company plans to advance the development of NS002 based on these findings. Positive interim results from the Phase 2 study could significantly enhance the company's product pipeline and market positioning.

Nasus Pharma Ltd. CEO issued a letter to shareholders outlining the company's strategic vision and goals for 2025, emphasizing advancements in product development and market expansion. The letter highlights the commitment to innovation and improving patient outcomes, while also addressing potential challenges in the pharmaceutical landscape. The CEO reassures shareholders of the company's dedication to enhancing shareholder value and maintaining a strong financial position. The CEO's strategic vision and goals for 2025 indicate significant future initiatives that could impact the company's trajectory and investor sentiment.

Nasus Pharma Ltd. has appointed Eyal Rubin as Executive Vice President and Chief Financial Officer, aiming to strengthen its leadership team. Rubin brings extensive experience in finance and strategic management, which is expected to enhance the company's financial operations and strategic initiatives. The appointment of a new CFO may moderately influence financial performance and strategic direction.

Nasus Pharma Ltd. has initiated a Phase 2 clinical study for its drug NS002, with the first participant successfully dosed. This study aims to evaluate the safety and efficacy of NS002 in treating patients, marking a significant step in the company's development pipeline. The initiation of a Phase 2 clinical study represents a major strategic move that could significantly impact the company's future and market performance.

Nasus Pharma Ltd. has received approval from Health Canada to initiate a Phase 2 clinical study for NS002, an intranasal epinephrine powder aimed at treating severe allergic reactions. This study is a significant step in the development of the product, which could enhance treatment options for patients experiencing anaphylaxis. Approval for a Phase 2 clinical study represents a significant advancement in product development and potential market entry.

Nasus Pharma Ltd. has announced an expanded agreement to support the development and commercialization of its NS002 intranasal epinephrine program. This collaboration aims to enhance the program's potential in treating severe allergic reactions, positioning Nasus Pharma for growth in the market for emergency allergy treatments. The expanded agreement is likely to significantly impact Nasus Pharma's future performance and market positioning in the allergy treatment sector.

Nasus Pharma Ltd. (NSRX) announced its upcoming presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The event is set to take place on September 11, 2023, and will feature a presentation by the company's management team, highlighting its strategic initiatives and business developments. The presentation may influence investor sentiment and provide insights into the company's strategic direction, but its overall impact is expected to be limited.

Nasus Pharma Ltd. celebrated its listing on the NYSE American with a bell ringing ceremony, marking a significant milestone for the company. This event highlights the company's commitment to growth and visibility in the public market, potentially attracting new investors and enhancing its market presence. The NYSE American listing is a major strategic move that could significantly enhance investor sentiment and market performance.

Nasus Pharma Ltd. (NSRX) has successfully closed its initial public offering (IPO), raising $10 million through the sale of 1 million shares at $10 per share. The company plans to use the proceeds to advance its clinical programs and for general corporate purposes. The IPO marks a significant milestone for Nasus Pharma as it seeks to enhance its visibility and access to capital markets. The successful IPO provides significant funding for clinical programs, potentially altering the company's growth trajectory.

Nasus Pharma Ltd. has announced the pricing of its initial public offering (IPO) at $10 million. The company aims to use the proceeds from the IPO to advance its product development and expand its operations. This move marks a significant step for Nasus Pharma as it seeks to enhance its market presence and financial stability. The IPO is a major strategic move that could significantly alter the company's trajectory and investor sentiment.